Dose-Response Metabolomics Unveils Liver Metabolic Disruptions and Pathway Sensitivity to Alkylimidazolium Ionic Liquids: Benchmark Dose Estimation for Health Risk Assessment DOI
Ming Li,

Kejia Wu,

Xiaole Zhao

et al.

Environmental Science & Technology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Alkylimidazolium-based ionic liquids (AILs), once hailed as ″green solvents,″ have seen widespread use, but recent concerns emerged regarding their environmental and health risks. This study integrates in vitro vivo dose-response metabolomics to investigate liver metabolic disturbances pathway sensitivity 1-octyl-3-methylimidazolium (M8OI) exposure. Important function indicators, including catalase, alanine aminotransferase, aspartate glycosylated serum protein, showed significant alterations (P < 0.05), indicating dysfunction. Metabolomics analysis revealed dose-dependent changes energy metabolism oxidative stress pathways both cell rat models, characterized by increased levels of thiamine lipopolysaccharides, decreased nicotinamide adenine. Key intermediates the tricarboxylic acid cycle, such citrate isocitrate, exhibited 0.05). Pathway identified disruptions arginine, proline, purine metabolism. Quantitative risk characterization based on effective concentration (EC) values key metabolites─adenine (EC-10 = 0.004 mg/kg), (±)12(13)-DiHOME 0.024 0.05 mg/kg) vivo, isocitrate 0.22 μM), d-threo-isocitric 0.23 citric 0.40 μM) vitro─as potential biomarkers M8OI-induced disruption. These findings highlight hepatic induced M8OI, with identifying benchmark dose regression thereby providing a basis for assessment.

Language: Английский

Dose-Response Metabolomics Unveils Liver Metabolic Disruptions and Pathway Sensitivity to Alkylimidazolium Ionic Liquids: Benchmark Dose Estimation for Health Risk Assessment DOI
Ming Li,

Kejia Wu,

Xiaole Zhao

et al.

Environmental Science & Technology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Alkylimidazolium-based ionic liquids (AILs), once hailed as ″green solvents,″ have seen widespread use, but recent concerns emerged regarding their environmental and health risks. This study integrates in vitro vivo dose-response metabolomics to investigate liver metabolic disturbances pathway sensitivity 1-octyl-3-methylimidazolium (M8OI) exposure. Important function indicators, including catalase, alanine aminotransferase, aspartate glycosylated serum protein, showed significant alterations (P < 0.05), indicating dysfunction. Metabolomics analysis revealed dose-dependent changes energy metabolism oxidative stress pathways both cell rat models, characterized by increased levels of thiamine lipopolysaccharides, decreased nicotinamide adenine. Key intermediates the tricarboxylic acid cycle, such citrate isocitrate, exhibited 0.05). Pathway identified disruptions arginine, proline, purine metabolism. Quantitative risk characterization based on effective concentration (EC) values key metabolites─adenine (EC-10 = 0.004 mg/kg), (±)12(13)-DiHOME 0.024 0.05 mg/kg) vivo, isocitrate 0.22 μM), d-threo-isocitric 0.23 citric 0.40 μM) vitro─as potential biomarkers M8OI-induced disruption. These findings highlight hepatic induced M8OI, with identifying benchmark dose regression thereby providing a basis for assessment.

Language: Английский

Citations

0